recombinant EMP2 antibodies and antibody fragments (UCLA)

N/A

Report date: 2025/03/20 09:43:23

Base Information

Drug Namerecombinant EMP2 antibodies and antibody fragments (UCLA)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragmentDiagnostic agent (In vivo)
Mechanisms of ActionEpithelial membrane protein 2 inhibitors
TargetsEpithelial membrane protein 2
Therapy Area/IndicationsBreast NeoplasmsCarcinoma, Endometrioid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of California, Los Angeles
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of California, Los Angeles
Inactive CompaniesN/A
Active IndicationsBreast NeoplasmsCarcinoma, Endometrioid
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A